The estimated Net Worth of China Growth Fund Iii L.P.I... is at least $4.88 Millón dollars as of 21 March 2018. China I owns over 3,086,418 units of CASI Pharmaceuticals Inc stock worth over $4,884,812 and over the last 12 years China sold CASI stock worth over $0.
Sign up
China I CASI stock SEC Form 4 insiders trading
China has made over 2 trades of the CASI Pharmaceuticals Inc stock since 2013, according to the Form 4 filled with the SEC. Most recently China bought 3,086,418 units of CASI stock worth $9,845,673 on 21 March 2018.
The largest trade China's ever made was buying 3,086,418 units of CASI Pharmaceuticals Inc stock on 21 March 2018 worth over $9,845,673. On average, China trades about 2,064,042 units every 920 days since 2013. As of 21 March 2018 China still owns at least 646,995 units of CASI Pharmaceuticals Inc stock.
You can see the complete history of China I stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Insiders trading at CASI Pharmaceuticals Inc
Over the last 12 years, insiders at CASI Pharmaceuticals Inc have traded over $0 worth of CASI Pharmaceuticals Inc stock and bought 30,834,178 units worth $51,898,666 . The most active insiders traders include Wei Wu He, Rajesh C Md Shrotriya y Pharmaceuticals Inc Spectru.... On average, CASI Pharmaceuticals Inc executives and independent directors trade stock every 91 days with the average trade being worth of $6,141,555. The most recent stock trade was executed by James Huang on 6 September 2022, trading 55,573 units of CASI stock currently worth $229,516.
What does CASI Pharmaceuticals Inc do?
CASI Pharmaceuticals, Inc. is a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products in China, the United States, and throughout the world. The Company is focused on acquiring, developing and commercializing products that augment its hematology oncology therapeutic focus as well as other areas of unmet medical need. The Company intends to execute its plan to become a leader by launching medicines in the Greater China market leveraging the Company’s China-based regulatory and commercial competencies and its global drug development expertise. The Company’s operations in China are conducted through its wholly-owned subsidiary, CASI Pharmaceuticals (China) Co., Ltd. (“CASI China”), which is located in Beijing, China. The Company has built a commercial team of over 70 hematology and oncology sales and marketing specialists based in China.
What does CASI Pharmaceuticals Inc's logo look like?
Complete history of China I stock trades at CASI Pharmaceuticals Inc
CASI Pharmaceuticals Inc executives and stock owners
CASI Pharmaceuticals Inc executives and other stock owners filed with the SEC include:
-
Wei-Wu He,
Executive Chairman of the Board, Chief Executive Officer -
Alexander Zukiwski,
Chief Medical Officer -
Wei Zhang,
President, President of CASI China, Interim Principal Financial Officer -
Dr. Wei-Wu He Ph.D.,
Chairman & CEO -
Dr. Wei Zhang Ph.D.,
Pres & Principal Financial Officer -
Dr. Alexander A. Zukiwski M.D.,
Exec. VP & Chief Medical Officer -
James Huang,
Independent Director -
Y. Alexander Wu,
Independent Director -
Franklin Salisbury,
Independent Director -
Quan Zhou,
Independent Director -
Rajesh Shrotriya,
Independent Director -
Amanda Cui,
VP & Global Controller -
Dr. James E. Goldschmidt Ph.D.,
Chief Bus. Devel. Officer -
Sara B. Capitelli CPA,
VP of Fin. -
Byte Ltdsnow Moon Ltdtianji...,
-
Ken Ren,
CEO and Director -
Pharmaceuticals Inc Spectru...,
-
Alex Wu,
Director -
Tak W. Mak,
Director -
China Growth Fund Iii L.P.I...,
-
Strategy Holding Ltd Wealth,
10% owner -
Sara B Capitelli,
VP, Finance & PAO -
George Chi,
Chief Financial Officer -
Cynthia W. Hu,
See Remarks -
Byte Ltdsnow Moon Ltdtianji...,
-
Ken Keyong Ren,
Chief Executive Officer -
Larry Zhang,
President -
Weihao Xu,
Chief Financial Officer